Gabriella Segal Lieberman

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Raymond L. Forbes, A. Astrup, F. Greenway, 2017, The Lancet.

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

John E. Poremba, H. Randeva, P. Borne, 2024, The Lancet.